Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
Follow TAK
Takeda Pharmaceutical Co. (TAK) Piotroski F-score
Takeda Pharmaceutical Co.'s Piotroski F-score for fiscal 2026 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 4 | (1.00) |
| FY2025 | 5 | 0.00 |
| FY2024 | 5 | (3.00) |
| FY2023 | 8 | 3.00 |
| FY2022 | 5 | (2.00) |
| FY2021 | 7 | 2.00 |
| FY2020 | 5 | 2.00 |
| FY2019 | 3 | (4.00) |
| FY2018 | 7 | 1.00 |
| FY2017 | 6 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (1.02%) | 0.72% | Fail | 0 |
| Positive operating cash flow | 6.87b | 6.98b | Pass | 1 |
| Rising return on assets | (1.02%) | 0.72% | Fail | 0 |
| Cash flow above net income | 7.88b | 6.27b | Pass | 1 |
| Falling long-term leverage | 0.29 | 0.26 | Fail | 0 |
| Rising current ratio | 1.09 | 1.01 | Pass | 1 |
| No new shares issued | 3,150,124,000 | 3,157,746,000 | Pass | 1 |
| Rising gross margin | 65.12% | 65.51% | Fail | 0 |
| Rising asset turnover | 0.30 | 0.30 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| UTHR United Therapeutics Corporation compare | 8 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 8 |
| HLN Haleon PLC Sponsored ADR compare | 8 |
| ZTS Zoetis Inc. compare | 7 |
| NBIX Neurocrine Biosciences, Inc. compare | 7 |
| ELAN Elanco Animal Health Incorporated compare | 5 |
| RDY Dr. Reddy's Laboratories Ltd compare | 4 |
| TAK Takeda Pharmaceutical Co. | 4 |
| VTRS Viatris Inc. compare | 4 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover